ESRA19-0701 Local anaesthetic (LAS) neurotoxicity after PNBS: current data

Strong, laboratory and clinical evidence of potential local anaesthetics (LAs) in situ neurotoxicity exists in literature. However, the relative importance of LAs toxicity to the generation of nerve injury is unknown and, data regarding the exact incidence of peripheral nerve damage, solely attribut...

Full description

Saved in:
Bibliographic Details
Published inRegional anesthesia and pain medicine Vol. 44; no. Suppl 1; pp. A48 - A50
Main Authors Moka, E, Makris, A, Theodoraki, K, Siafaka, I, Vadalouca, A
Format Journal Article
LanguageEnglish
Published Secaucus BMJ Publishing Group LTD 01.10.2019
Subjects
Online AccessGet full text
ISSN1098-7339
1532-8651
DOI10.1136/rapm-2019-ESRAABS2019.46

Cover

Loading…
Abstract Strong, laboratory and clinical evidence of potential local anaesthetics (LAs) in situ neurotoxicity exists in literature. However, the relative importance of LAs toxicity to the generation of nerve injury is unknown and, data regarding the exact incidence of peripheral nerve damage, solely attributed to LAs induced direct neurotoxicity, are lacking. Interestingly, data do exist regarding percentages of nerve injury following peripheral nerve blocks (PNBs), with the overall incidence of neurological complications of any severity being low, and with studies estimating them below 3:100 (3 over a hundred) in the case of single shot blocks, and between 0.4 and 2% in the case of peripheral nerve catheters (PNCs). Most of these neurological complications are minor, transient sensory deficits, with permanent injury being very rare. Large prospective/retrospective studies, examining neurological complications in PNBs estimate that mild paraesthesias can be encountered in up to 15% of patients, with a complete spontaneous resolution of the majority of symptoms within days to weeks, and the encouraging report that in 99% of patients, symptoms resolve completely within 1 year. the reported incidence however varies considerably between studies and over time, possibly due to methods used to capture anaesthesia related neurologic complications, but according to the majority of authors, long term neurological injury is extremely rare, with the estimated incidence ranging between 0.024 and 0.04%.LAs capacity to damage neuronal cells remains unclear. Not only LAs, but multiple risk factors other than drugs themselves are involved, contributing to the risk of neurologic injury, with neurological function after a PNB being the net result of the interplay between all associated risk factors. By using the well-known triad model, the complex phenomenon of neurologic injury seems to result from a complicated interaction among host-patient factors (anatomic, biologic and comorbidities), causative agents (mechanical, ischaemic, and chemical neurotoxic insults) and environmental factors (RA tools, guidance techniques, supervision, safe practice culture). the neurologic injury may subsequently represent the result-final outcome of a chain of interactions among these risk factors. Minimization or elimination of any of the triangle’s components may potentially, in theory, interrupt the interaction and reduce the likelihood of the injury or possibly prevent it entirely. the individual risk factors present in this chain are themselves either contributory or necessary for the outcome to occur. Although we have classified the relevant risk factors for neurologic complications as being specific to the host, agent, or environment, whether each individual risk factor is just contributory or is necessary for event causation needs to be determined in the future. Hence, the safest approach appears to be identification and prevention of all potential risk factors. Many of the factors responsible for neurologic complications are non-modifiable, meaning that screening for at-risk patients is necessary.LAs have a potential for neurotoxicity (in vitro, in vivo, on cell lines and animal models and few existing human studies/clinical reports, case series or cadaveric studies). Precise pathophysiology mechanisms have not yet been fully understood, although the majority of investigators agree that in situ neurotoxicity is probably mediated by mechanisms other than VGSC and GPCR blockade. LAs can induce neurotoxicity mediated by direct pleiotropic effects on neuronal tissue ultrastructure. When when injected directly into the nerve or the adjacent tissues, LAs can cause an acute inflammatory reaction, collagen disarray or recurrent fibrosis that indirectly involves the nerve. Current histopathological studies suggest multiple types of nerve cell damage, induced by LAs, effects on nerve cells body, membrane solubilization and lysis, apoptosis, necrosis, myelin architecture disruption, wallerian degeneration, demyelination, myelin globules formation, focal myelin loss, effects on nerve fibres and axons (reduced density and loss), oedema, degeneration, schwann cell injury, electrophysiological effects (delay in axonal conductivity), effects on edge of growing nerve fibres and regenerating neurons, growth cone collapse, distal neurites destruction and fragmentation, as well as retraction of cell extension.In reference to cell ultrastructure, LAs induce a large spectrum of abnormalities. In this context, lidocaine, ropivacaine, and bupivacaine reduced the number of neurons. Moreover, incubation of the axonal compartment with 40mM lidocaine for 24 h, induced axonal degeneration with retraction of distal neuritis and fragmentation of neuritis. Additionally, in SH-SY5Y cells, 20 min treatment with 10mM lidocaine induced retraction of the cell extension. Continuous infusions of 0.5–0.75% bupivacaine for 72 h in the vicinity of the sciatic nerves of rats induced severe wallerian degeneration, with varying degrees of disruption of the normal myelin architecture, formation of myelin globules and vacuolization, and focal loss of myelin staining. Lastly, infusion of 600mM lidocaine just outside of the perineurium was associated with swollen axons, macrophage phagocytosis of degenerated tissue, and epineurial and endoneurial collagen. LAs also exert effects on neuronal microenvironment and have an impact on energy and cell metabolism, with disturbances of a diversity of cellular processes that may contribute to neuronal damage by LAs, although no single pathway is established as the clinically dominant mechanism. Even if detailed subcellular pathways of neurotoxicity have been the subject of substantial research efforts, the ‘big’ picture is still unclear.Altered Ca++ homeostasis and elevated intracellular calcium levels may play a central role. Disruption of cytoplasmic calcium signaling after LAs injection induces elevations in cytoplasmic calcium C, through plasmalemmal influx and release of calcium from intracellular stores, leading to axonal transport inhibition, membrane lysis and neuronal death from activation of kinases and altered energy metabolism.Additionally, LAs affect mitochondrial bioenergetics, and inhibit mitochondrial energy metabolism due to increased permeability of mitochondrial membrane, collapse of mitochondrial membrane potential (ΔΨ), decreased ATP synthesis (ATP depletion) and reduction of respiratory chain protein content that is localized in the inner mitochondrial membrane. Consequently, oxidative phosporylation uncoupling, mitochondrial network fragmentation and mitophagy take place, cytochrome c is released and intrinsic caspase pathway is activated, potentially resulting in nerve cells apoptosis.An important feature of LAs neurotoxicity is oxidative stress of endoplasmatic reticulum and the over production of oxygen free radicals–ROS, that can further provoke cellular damage, in terms of apoptosis (programmed cell death), or rapid necrosis especially of schwann cells.Recent studies indicate that preapoptotic enzymes such as those included the p38 MAPK pathway, might also play a central role in LAs induced neurotoxicity. the p38 MAPK phosphorylation induced by LAs, is involved in apoptosis regulation, gene expression, mitosis, DNA fragmentation, transcription and finally cell death, by an increase of CHOP (C homologous protein), which among other actions, inhibits bcl2 antiapoptotic protein, which normally counteracts cytochrome c release.Finally, another group of molecular targets that is involved in apoptosis inhibition is the Akt–ERK Pathway, playing a pivotal role in cell survival. LAs inhibit Akt and ERK, leading to reduced cell survival, and increased apoptotic activity, whereas their phosphorylation can protect form LAs induced nerve damage.In reference to dose, concentration and duration of exposure to LAs, neurotoxicity induction has been reported for several LAs, both in vitro, in various cell culture models, such as neuroblastoma, human neuronal, swan, DRG, human lymphocytes and T-lymphoma cell lines, as well as in vivo, in animal models in rats, mainly involving the sciatic nerve. According to the majority of experimental studies results, all commonly used LAs can trigger neuronal apoptosis and may decrease cell viability in clinically relevant C, or even at C well below those applied in clinical practice, whereas, higher C of LAs may cause rapid cell death and late stage apoptosis, primarily due to necrosis. LAs neurotoxicity is induced in a dose, time and concentration dependent manner, with all LAs, exerting similar rates of early apoptotic cell formation at low concentrations. In this context, probably, exposure to very high concentration for a very short time leads to a greater predominance of necrotic cell death, whereas, during long term exposure of neurons, apoptosis is possibly the major mechanism of cell death. In addition, prolonged exposure of high doses and high concentrations may finally result in – may be the cause of – permanent nerve injuries.Moreover, according to current literature, a great variability of in situ neuroapoptotic-neurotoxic properties among LAs has been suggested by several experimental studies. Interestingly, it seems that LAs neurotoxicity is strongly correlated with lipid solubility (lipophilicity-octanol buffer coefficient) and thus conduction blocking potency, either experimental or clinical. on the contrary, a low degree of correlation has been noticed between LAs neurotoxicity and pKa, protein binding or MW, whereas, neurotoxicity is independent of chemical class and structural factors (amide/ester linkage), with stereospecificity also having no influence on nerve cells cytotoxicity. as such, although S-enantiomers are indeed advantageous with regard to LAST, it seems they offer no advantage in respect to LAs’ in situ toxicity. Furthermore, a comparison of LD50 values of different LAs (in
AbstractList Strong, laboratory and clinical evidence of potential local anaesthetics (LAs) in situ neurotoxicity exists in literature. However, the relative importance of LAs toxicity to the generation of nerve injury is unknown and, data regarding the exact incidence of peripheral nerve damage, solely attributed to LAs induced direct neurotoxicity, are lacking. Interestingly, data do exist regarding percentages of nerve injury following peripheral nerve blocks (PNBs), with the overall incidence of neurological complications of any severity being low, and with studies estimating them below 3:100 (3 over a hundred) in the case of single shot blocks, and between 0.4 and 2% in the case of peripheral nerve catheters (PNCs). Most of these neurological complications are minor, transient sensory deficits, with permanent injury being very rare. Large prospective/retrospective studies, examining neurological complications in PNBs estimate that mild paraesthesias can be encountered in up to 15% of patients, with a complete spontaneous resolution of the majority of symptoms within days to weeks, and the encouraging report that in 99% of patients, symptoms resolve completely within 1 year. the reported incidence however varies considerably between studies and over time, possibly due to methods used to capture anaesthesia related neurologic complications, but according to the majority of authors, long term neurological injury is extremely rare, with the estimated incidence ranging between 0.024 and 0.04%.LAs capacity to damage neuronal cells remains unclear. Not only LAs, but multiple risk factors other than drugs themselves are involved, contributing to the risk of neurologic injury, with neurological function after a PNB being the net result of the interplay between all associated risk factors. By using the well-known triad model, the complex phenomenon of neurologic injury seems to result from a complicated interaction among host-patient factors (anatomic, biologic and comorbidities), causative agents (mechanical, ischaemic, and chemical neurotoxic insults) and environmental factors (RA tools, guidance techniques, supervision, safe practice culture). the neurologic injury may subsequently represent the result-final outcome of a chain of interactions among these risk factors. Minimization or elimination of any of the triangle’s components may potentially, in theory, interrupt the interaction and reduce the likelihood of the injury or possibly prevent it entirely. the individual risk factors present in this chain are themselves either contributory or necessary for the outcome to occur. Although we have classified the relevant risk factors for neurologic complications as being specific to the host, agent, or environment, whether each individual risk factor is just contributory or is necessary for event causation needs to be determined in the future. Hence, the safest approach appears to be identification and prevention of all potential risk factors. Many of the factors responsible for neurologic complications are non-modifiable, meaning that screening for at-risk patients is necessary.LAs have a potential for neurotoxicity (in vitro, in vivo, on cell lines and animal models and few existing human studies/clinical reports, case series or cadaveric studies). Precise pathophysiology mechanisms have not yet been fully understood, although the majority of investigators agree that in situ neurotoxicity is probably mediated by mechanisms other than VGSC and GPCR blockade. LAs can induce neurotoxicity mediated by direct pleiotropic effects on neuronal tissue ultrastructure. When when injected directly into the nerve or the adjacent tissues, LAs can cause an acute inflammatory reaction, collagen disarray or recurrent fibrosis that indirectly involves the nerve. Current histopathological studies suggest multiple types of nerve cell damage, induced by LAs, effects on nerve cells body, membrane solubilization and lysis, apoptosis, necrosis, myelin architecture disruption, wallerian degeneration, demyelination, myelin globules formation, focal myelin loss, effects on nerve fibres and axons (reduced density and loss), oedema, degeneration, schwann cell injury, electrophysiological effects (delay in axonal conductivity), effects on edge of growing nerve fibres and regenerating neurons, growth cone collapse, distal neurites destruction and fragmentation, as well as retraction of cell extension.In reference to cell ultrastructure, LAs induce a large spectrum of abnormalities. In this context, lidocaine, ropivacaine, and bupivacaine reduced the number of neurons. Moreover, incubation of the axonal compartment with 40mM lidocaine for 24 h, induced axonal degeneration with retraction of distal neuritis and fragmentation of neuritis. Additionally, in SH-SY5Y cells, 20 min treatment with 10mM lidocaine induced retraction of the cell extension. Continuous infusions of 0.5–0.75% bupivacaine for 72 h in the vicinity of the sciatic nerves of rats induced severe wallerian degeneration, with varying degrees of disruption of the normal myelin architecture, formation of myelin globules and vacuolization, and focal loss of myelin staining. Lastly, infusion of 600mM lidocaine just outside of the perineurium was associated with swollen axons, macrophage phagocytosis of degenerated tissue, and epineurial and endoneurial collagen. LAs also exert effects on neuronal microenvironment and have an impact on energy and cell metabolism, with disturbances of a diversity of cellular processes that may contribute to neuronal damage by LAs, although no single pathway is established as the clinically dominant mechanism. Even if detailed subcellular pathways of neurotoxicity have been the subject of substantial research efforts, the ‘big’ picture is still unclear.Altered Ca++ homeostasis and elevated intracellular calcium levels may play a central role. Disruption of cytoplasmic calcium signaling after LAs injection induces elevations in cytoplasmic calcium C, through plasmalemmal influx and release of calcium from intracellular stores, leading to axonal transport inhibition, membrane lysis and neuronal death from activation of kinases and altered energy metabolism.Additionally, LAs affect mitochondrial bioenergetics, and inhibit mitochondrial energy metabolism due to increased permeability of mitochondrial membrane, collapse of mitochondrial membrane potential (ΔΨ), decreased ATP synthesis (ATP depletion) and reduction of respiratory chain protein content that is localized in the inner mitochondrial membrane. Consequently, oxidative phosporylation uncoupling, mitochondrial network fragmentation and mitophagy take place, cytochrome c is released and intrinsic caspase pathway is activated, potentially resulting in nerve cells apoptosis.An important feature of LAs neurotoxicity is oxidative stress of endoplasmatic reticulum and the over production of oxygen free radicals–ROS, that can further provoke cellular damage, in terms of apoptosis (programmed cell death), or rapid necrosis especially of schwann cells.Recent studies indicate that preapoptotic enzymes such as those included the p38 MAPK pathway, might also play a central role in LAs induced neurotoxicity. the p38 MAPK phosphorylation induced by LAs, is involved in apoptosis regulation, gene expression, mitosis, DNA fragmentation, transcription and finally cell death, by an increase of CHOP (C homologous protein), which among other actions, inhibits bcl2 antiapoptotic protein, which normally counteracts cytochrome c release.Finally, another group of molecular targets that is involved in apoptosis inhibition is the Akt–ERK Pathway, playing a pivotal role in cell survival. LAs inhibit Akt and ERK, leading to reduced cell survival, and increased apoptotic activity, whereas their phosphorylation can protect form LAs induced nerve damage.In reference to dose, concentration and duration of exposure to LAs, neurotoxicity induction has been reported for several LAs, both in vitro, in various cell culture models, such as neuroblastoma, human neuronal, swan, DRG, human lymphocytes and T-lymphoma cell lines, as well as in vivo, in animal models in rats, mainly involving the sciatic nerve. According to the majority of experimental studies results, all commonly used LAs can trigger neuronal apoptosis and may decrease cell viability in clinically relevant C, or even at C well below those applied in clinical practice, whereas, higher C of LAs may cause rapid cell death and late stage apoptosis, primarily due to necrosis. LAs neurotoxicity is induced in a dose, time and concentration dependent manner, with all LAs, exerting similar rates of early apoptotic cell formation at low concentrations. In this context, probably, exposure to very high concentration for a very short time leads to a greater predominance of necrotic cell death, whereas, during long term exposure of neurons, apoptosis is possibly the major mechanism of cell death. In addition, prolonged exposure of high doses and high concentrations may finally result in – may be the cause of – permanent nerve injuries.Moreover, according to current literature, a great variability of in situ neuroapoptotic-neurotoxic properties among LAs has been suggested by several experimental studies. Interestingly, it seems that LAs neurotoxicity is strongly correlated with lipid solubility (lipophilicity-octanol buffer coefficient) and thus conduction blocking potency, either experimental or clinical. on the contrary, a low degree of correlation has been noticed between LAs neurotoxicity and pKa, protein binding or MW, whereas, neurotoxicity is independent of chemical class and structural factors (amide/ester linkage), with stereospecificity also having no influence on nerve cells cytotoxicity. as such, although S-enantiomers are indeed advantageous with regard to LAST, it seems they offer no advantage in respect to LAs’ in situ toxicity. Furthermore, a comparison of LD50 values of different LAs (in
Author Vadalouca, A
Moka, E
Theodoraki, K
Siafaka, I
Makris, A
Author_xml – sequence: 1
  givenname: E
  surname: Moka
  fullname: Moka, E
  organization: Creta InterClinic Hospital, Anaesthesiology Department, Heraklion, Crete, Greece
– sequence: 2
  givenname: A
  surname: Makris
  fullname: Makris, A
  organization: Asklepieiion General Hospital, Anaesthesiology Department, Athens, Greece
– sequence: 3
  givenname: K
  surname: Theodoraki
  fullname: Theodoraki, K
  organization: Aretaieion University Hospital, A’ Anaesthesiology Clinic, Pain Therapy and Palliative Care Centre, Athens, Greece
– sequence: 4
  givenname: I
  surname: Siafaka
  fullname: Siafaka, I
  organization: Aretaieion University Hospital, A’ Anaesthesiology Clinic, Pain Therapy and Palliative Care Centre, Athens, Greece
– sequence: 5
  givenname: A
  surname: Vadalouca
  fullname: Vadalouca, A
  organization: Aretaieion University Hospital, A’ Anaesthesiology Clinic, Pain Therapy and Palliative Care Centre, Athens, Greece
BookMark eNpNkM1OwzAQhC1UJNrCO1jiAgcXO2s7CbcUlR8pAkR6t-zEFqnapDiJRG9ceFGeBEflwGnnMLO7883QpGkbixBmdMEYyBuv9zsSUZaSVfGWZcti1AsuT9CUCYhIIgWbBE3ThMQA6Rmadd2GUprEXE5RPqZCmMaU_Xx9522pt1g32nb9u-3rEl_lWXGNGzv4tm8_67LuD1i73nr8-rwsbnE5eG-bHle61-fo1OltZy_-5hyt71fru0eSvzw83WU5MXEERBvD4lgbx7QTQoOTUUKdAwBZGgYVuBSEdI5WHKpU0CSJJQ_S0NKmleEwR5fHtXvffgzhU7VpB9-EiyoSAkJVySG44Ogyu43a-3qn_UExqkZqaqSmRlLqHzXFJfwCCu1iNg
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Copyright_xml – notice: Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
– notice: 2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
DBID 3V.
7RV
7X7
7XB
88E
88I
8AF
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
M0S
M1P
M2P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
S0X
DOI 10.1136/rapm-2019-ESRAABS2019.46
DatabaseName ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni)
Medical Database
Science Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
SIRS Editorial
DatabaseTitle ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
SIRS Editorial
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList
ProQuest Central Student
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1532-8651
EndPage A50
ExternalDocumentID rapm
Genre Conference Proceeding
GroupedDBID ---
--K
.GJ
.Z2
026
0R~
123
1B1
1~5
29P
4.4
4G.
53G
5RE
5VS
7-5
7RV
7X7
88E
88I
8AF
8AO
8FI
8FJ
8FW
8R4
8R5
AAEDT
AAHLL
AAKAS
AALRI
AAQFI
AAQXK
AARTV
AAWTL
AAXUO
ABBUW
ABJNI
ABMAC
ABUWG
ABWVN
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACGOD
ACRPL
ACWDW
ACWRI
ACXNZ
ADBBV
ADMUD
ADNMO
ADZCM
AE3
AE6
AENEX
AFKRA
AFTRI
AGINI
AGQPQ
AHMBA
AITUG
AIZYK
AJNYG
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZFZN
AZQEC
BENPR
BKEYQ
BPHCQ
BQLVK
BVXVI
CAG
CCPQU
COF
CS3
CXRWF
DU5
DWQXO
E.X
EBS
EJD
EO8
EO9
EX3
F5P
FDB
FEDTE
FGOYB
FL-
FYUFA
G-Q
GNUQQ
HAJ
HCIFZ
HMCUK
HVGLF
HZ~
IHE
IN~
JK8
K8S
KD2
L-C
M18
M1P
M2P
M2Q
M41
N9A
NAPCQ
NQ-
NXWIF
O9-
OCUKA
OHYEH
ORVUJ
OUVQU
OVD
OXXIT
P2P
PCD
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R2-
RIG
RMJ
ROL
RPZ
RWL
S0X
S4S
SDG
SDP
SEW
SJN
SSZ
TAE
TEORI
UHS
UKHRP
V2I
W3M
WOW
X3V
X3W
ZGI
ZXP
3V.
7XB
8FK
AERUA
K9.
PHGZM
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
Q9U
ID FETCH-LOGICAL-b723-abb177abf1af55a3f6280ff3336cb13d3f9356ff0d43d9508876443db0ce9db43
IEDL.DBID 7X7
ISSN 1098-7339
IngestDate Sat Aug 16 15:22:24 EDT 2025
Fri Apr 25 03:28:42 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue Suppl 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b723-abb177abf1af55a3f6280ff3336cb13d3f9356ff0d43d9508876443db0ce9db43
Notes ObjectType-Conference Proceeding-1
SourceType-Scholarly Journals-1
content type line 14
PQID 2553109643
PQPubID 47693
ParticipantIDs proquest_journals_2553109643
bmj_primary_10_1136_rapm_2019_ESRAABS2019_46
PublicationCentury 2000
PublicationDate 20191000
20191001
PublicationDateYYYYMMDD 2019-10-01
PublicationDate_xml – month: 10
  year: 2019
  text: 20191000
PublicationDecade 2010
PublicationPlace Secaucus
PublicationPlace_xml – name: Secaucus
PublicationTitle Regional anesthesia and pain medicine
PublicationYear 2019
Publisher BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group LTD
SSID ssj0008746
Score 2.2526212
Snippet Strong, laboratory and clinical evidence of potential local anaesthetics (LAs) in situ neurotoxicity exists in literature. However, the relative importance of...
SourceID proquest
bmj
SourceType Aggregation Database
Publisher
StartPage A48
SubjectTerms Anesthesia
Apoptosis
Cytochrome
Gene expression
Kinases
Local anesthesia
Metabolism
Neurotoxicity
Patients
Permeability
Phosphorylation
Proteins
Risk factors
Toxicity
Title ESRA19-0701 Local anaesthetic (LAS) neurotoxicity after PNBS: current data
URI https://rapm.bmj.com/content/44/Suppl_1/A48.full
https://www.proquest.com/docview/2553109643
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NS8NAEF20BfEifmK1lj14UHBt0kk2WS_SSkuRtpS2Qm9hN5tFhKa1raA3L_5Rf4mZbaqC4C0Qsoc32XmzszNvCDkPExE6CQgmPEcyT3uahdKPmSuMDEDE3EhM6Hd7vP3g3Y_9cZ5wW-RllWufaB21nsaYI69moS-KWGYEejt7Zjg1Cm9X8xEam6SI0mVY0hWMvw9cThisuousZiaAWFfyAK_O5WyS_SGuYM3hoF5vDPH5GsPgTTV5-uOYLdu0dslOHibS-sque2QjSffJVje_CD8gHVzPNgY57uf7RwcZicpUZks9YlsivejUh5fUqlUup6_ZV8s3aueB036vMbyh8UqXiWKF6CEZtZqjuzbLByMwFdSASYWaUVIZVxrfl2B4LXSMAQAeKxc0GAE-N8bRHmg75TXIoh7QyokToZUHR6SQTtPkmFA_cV2V1GIwMvSMBiUCVyopAyRvw8MSucrgiGYr5YvInhiAR4hehIhFv9CLPF4i5TVuUb4XFtGP5U7-f31Ktq1FbKlcmRSW85fkLKP8papYu1ZIsdHs9QdfhwOojA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1faxQxEB_aK6gv4l9aWzUPCgrG7u5ksxuhyJ1eudq9o_RO6FtINgki9O7anmjffPHj-KX6SUyyuyoIvvVtYdl5mJmd-U0y8xuAZ6UVZWJRUMESRZlhhpYqr2kqnCpQ1NypcKA_nvDRR_bhJD9Zg5_dLExoq-xiYgzUZlGHM_JdD30DiaVPoG-XZzRsjQq3q90KjcYtDu3lV1-yXewdvPf2fZ5l-8PZuxFttwpQXWRIlQ6ES0q7VLk8V-h4VibOISKvdYoGncCcO5cYhiauSC08ZECjk9oKoxl6seuwwdBXMj3YGAwnR8e_Q39ZNONMkaQTUXStQ8h3z9Xy1LtkKuhwetzvD6bh-XXA3ev69PM_mSCmt_07cLvFpaTfONJdWLPze3Bj3N6834cqyIuTSEl69f1HFVIgUXPlRX0Kc5DkRdWfviSRHnO1-Oa_Wl2SuICcHE0G0zekboigSGhJfQCz69DZQ-jNF3O7CSS3aaptVqNTJXMGtShSpZUqAlpwvNyCV14dctlQbchYoiCXQXsyaEz-pT3J-BbsdHqT7c93If-4yqP_v34KN0ezcSWrg8nhNtyK1ol9ejvQW51_sY893ljpJ62VCchr9qtf6Qzkxw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1faxQxEB_aCsUX8S9Wq-ZBQcF4m53d7EYQudoerb0exatwbyHZJIjQu7M90b754ofy6_hJzGR3VRB869tC2Hn4zSQzk8z8BuBx7VWdeVRcFZnhhSscr03ZcKGCqVA1Mhi60D-ayP33xdtZOVuDH30vDJVV9mdiOqjdoqE78kEMfYnEMjrQQejKIo53R6-XnzhNkKKX1n6cRmsih_7iS0zfzl8d7EZdP8nz0d7Jm33eTRjgtsqRG0vkS8YGYUJZGgwyr7MQEFE2VqDDoLCUIWSuQJfGpVYxfEBns8YrZwuMYtfhSoWloC1WzX7nelldtY1Nia4TUfVFRCgHZ2Z5Go1TKL43fTcc7kzp-wVF4Ov29OM_PiE5utF1uNZFqGzYmtQNWPPzm7B51L3B34IxyUs9SZn4-e37mJwhM3MTRX2gjkj2dDycPmOJKHO1-Br_Wl2wNIqcHU92pi9Z01JCMSpOvQ0nl4HYHdiYL-b-LrDSC2F93mAwdREcWlUJY42pKG4Ist6C5xEOvWxJN3RKVlBqQk8TYvov9HQht2C7x0132_Bc_zGae_9ffgSb0Zr0-GByeB-uJuWkgr1t2FidffYPYuCxsg-TihnoSzapX1jT55c
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ESRA19-0701%E2%80%85Local+anaesthetic+%28LAS%29+neurotoxicity+after+PNBS%3A+current+data&rft.jtitle=Regional+anesthesia+and+pain+medicine&rft.au=Moka%2C+E&rft.au=Makris%2C+A&rft.au=Theodoraki%2C+K&rft.au=Siafaka%2C+I&rft.date=2019-10-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=1098-7339&rft.eissn=1532-8651&rft.volume=44&rft.issue=Suppl+1&rft.spage=A48&rft.epage=A50&rft_id=info:doi/10.1136%2Frapm-2019-ESRAABS2019.46&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-7339&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-7339&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-7339&client=summon